<DOC>
	<DOC>NCT01583738</DOC>
	<brief_summary>Assessment of efficacy and tolerance of a new anti-dizziness drug in acute vertigo.</brief_summary>
	<brief_title>Effect of V0251 in Acute Vertigo</brief_title>
	<detailed_description />
	<mesh_term>Vertigo</mesh_term>
	<mesh_term>Dizziness</mesh_term>
	<criteria>Men or women Age 18 to 70 years Acute vertigo attack due to vestibular disorder Signs of brain, brainstem and/or cerebellar dysfunction Concomitant central neurological disorder Psychogenic vertigo Use of ototoxic drugs causing vertigo or dizziness within the last month Use of antidizziness medications from the onset of symptoms, except if the dosage had been stable for at least 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>